Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 12 2021
06 12 2021
Historique:
received:
02
08
2021
accepted:
09
11
2021
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Selection criteria included studies evaluating efficacy and safety outcomes of medical cannabinoids (tetrahydrocannabinol, cannabidiol and other cannabis derivatives) versus control in children, independently assessed by two reviewers. Eight studies were included, all of which are randomized controlled trials. Cannabidiol is associated with 50% reduction in seizures rate (Relative Risk (RR) = 1.69, 95% CI [1.20-2.36]) and caregiver global impression of change (Median Estimated difference = (- 1), 95%CI [- 1.39-(- 0.60)]) in Dravet syndrome, compared to placebo. While cannabidiol was associated with a reduction in reported seizure events (RR = 0.59, 95% CI [0.36-0.97]), no association was found in products contained also tetrahydrocannabinol (RR = 1.35, 95% CI [0.46-4.03]). Higher dose of cannabidiol was associated with decreased appetite (RR = 2.40, 95% CI [1.39-4.15]). A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. However, cannabidiol is also associated with decreased appetite. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.
Identifiants
pubmed: 34873203
doi: 10.1038/s41598-021-02770-6
pii: 10.1038/s41598-021-02770-6
pmc: PMC8648720
doi:
Substances chimiques
Cannabinoids
0
Medical Marijuana
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23462Informations de copyright
© 2021. The Author(s).
Références
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Cureus. 2019 Jun 26;11(6):e5006
pubmed: 31497436
BMJ. 2001 Jul 7;323(7303):16-21
pubmed: 11440936
Rambam Maimonides Med J. 2020 Jan 30;11(1):
pubmed: 32017679
Nat Med. 2020 Oct;26(10):1536-1540
pubmed: 32778828
Neurosci Lett. 2011 Feb 18;490(1):82-4
pubmed: 21172406
Epilepsy Behav. 2020 Jan;102:106635
pubmed: 31731110
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
JAMA Neurol. 2020 May 1;77(5):613-621
pubmed: 32119035
Psychol Med. 2014 Mar;44(4):797-810
pubmed: 23795762
Sci Rep. 2017 Sep 5;7(1):10516
pubmed: 28874764
Pediatrics. 2017 Nov;140(5):
pubmed: 29061872
Drug Alcohol Depend. 2017 Aug 1;177:1-13
pubmed: 28549263
J Emerg Med. 2011 Sep;41(3):e69-71
pubmed: 20634020
J Pediatr. 2017 Nov;190:142-152
pubmed: 28888560
Br J Clin Pharmacol. 2021 Feb;87(2):436-446
pubmed: 32478863
Br J Pharmacol. 2005 Jun;145(3):293-300
pubmed: 15778743
Schizophr Res. 2014 Aug;157(1-3):266-70
pubmed: 24930951
Arch Dis Child. 1986 May;61(5):502-5
pubmed: 3013104
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
Early Interv Psychiatry. 2018 Dec;12(6):1013-1023
pubmed: 29927066
Pediatrics. 2012 Aug;130(2):285-92
pubmed: 22826574
Neurotherapeutics. 2015 Oct;12(4):692-8
pubmed: 26271952
PLoS Med. 2016 May 24;13(5):e1002028
pubmed: 27218655
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:637-659
pubmed: 31580774
Neurology. 2018 Apr 3;90(14):e1204-e1211
pubmed: 29540584
Biol Sex Differ. 2018 Jun 11;9(1):22
pubmed: 29891008
Cannabis Cannabinoid Res. 2018 Mar 01;3(1):21-34
pubmed: 29607408
Neurol Sci. 2018 Mar;39(3):403-414
pubmed: 29124439
Int J Mol Sci. 2018 Mar 13;19(3):
pubmed: 29533978
Children (Basel). 2019 Jun 17;6(6):
pubmed: 31212902
Stat Med. 2007 Apr 30;26(9):1964-81
pubmed: 16955539
N Engl J Med. 2018 May 17;378(20):1888-1897
pubmed: 29768152
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Pediatrics. 2019 Feb;143(2):
pubmed: 30670581
N Engl J Med. 2017 May 25;376(21):2011-2020
pubmed: 28538134
J Int Med Res. 2018 Jun;46(6):2149-2156
pubmed: 29690798
Mol Autism. 2021 Feb 3;12(1):6
pubmed: 33536055
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
Pediatrics. 1987 Jun;79(6):946-52
pubmed: 3035479
Inflamm Bowel Dis. 2019 Feb 21;25(3):427-435
pubmed: 30358848
Neurosci Biobehav Rev. 2017 Jan;72:310-324
pubmed: 27884751
Dev Med Child Neurol. 2020 Sep;62(9):1031-1039
pubmed: 32342496
Nefrologia. 2015;35(3):328-9
pubmed: 26299175
Neuropsychopharmacology. 2020 Oct;45(11):1799-1806
pubmed: 32268347
Eur J Emerg Med. 2006 Jun;13(3):177-9
pubmed: 16679885
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Epilepsia. 2011 Apr;52 Suppl 2:95-101
pubmed: 21463290
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Autism Dev Disord. 2017 Feb;47(2):439-446
pubmed: 27866350
J Autism Dev Disord. 2019 Mar;49(3):1284-1288
pubmed: 30382443
Epilepsy Behav. 2018 Mar;80:240-246
pubmed: 29429908
Curr Neuropharmacol. 2019;17(10):974-989
pubmed: 31161980
J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):741-753
pubmed: 29511052
BMC Med Res Methodol. 2009 Dec 30;9:86
pubmed: 20042080
Drugs. 2018 Nov;78(17):1791-1804
pubmed: 30390221
Int J Mol Sci. 2021 Jul 12;22(14):
pubmed: 34299069
Pediatr Emerg Care. 2005 Aug;21(8):527-8
pubmed: 16096599